Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07521124

ABC Maintenance Therapy for AML

Study Objectives:

To evaluate the Relapse-Free Survival (RFS) and 1-year RFS rate in patients with Acute Myeloid Leukemia (AML) receiving maintenance therapy with Chidamide combined with Venetoclax and Azacitidine.

Study Design:

Prospective, Multicenter, Interventional Cohort Study.

Total Enrollment:

104 subjects. Cohort 1 (MRD-Negative Patients): 61 subjects Chidamide (C): 5 mg, orally, once daily, Days 1-14. Azacitidine (A): 50 mg/m², subcutaneous injection, Days 1-5. Venetoclax (B): 400 mg, orally, once daily (QD), Days 1-14. Cycle: 28 days per cycle, for a total of 12 cycles. Cohort 2 (MRD-Persistent Positive Patients): 43 subjects Chidamide (C): 5 mg, orally, once daily, Days 1-28. Azacitidine (A): 50 mg/m², subcutaneous injection, Days 1-5. Venetoclax (B): 400 mg, orally, once daily (QD), Days 1-14. Cycle: 28 days per cycle, for a total of 12 cycles.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Acute Myeloid Leukemia (AML) in Remission Hematologic Diseases Hemic and Lymphatic Diseases Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasms Neoplasms by Histologic Type

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Union Hospital, Tongji Medical College, Huazhong University of Science and Technolog

Wuhan, China

Location contact

Weiming Li, Ph.D.

CONTACT

[email protected]

027-85726375

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 18 to 80 years with newly diagnosed Acute Myeloid Leukemia (AML)
  • Patients who have achieved their first Complete Remission (CR) or Complete Remission with incomplete hematologic recovery (CRi) at the time of enrollment, following induction therapy with intensive chemotherapy and at least 2 cycles of consolidation therapy. Remission must have been achieved within 4 months (±7 days) prior to enrollment.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3.
  • Women of childbearing potential are eligible if they meet the following conditions:
  • A negative serum or urine pregnancy test is performed within 10-14 days prior to enrollment, and a second negative pregnancy test is performed within 24 hours prior to the initiation of treatment. Both negative results are required to meet the criteria for treatment initiation.
  • They agree to practice abstinence or use two effective methods of contraception during the treatment period and for 28 days after discontinuation of the study drug.
  • Male patients with female partners of childbearing potential are eligible if they agree to practice abstinence or use two effective methods of contraception during the treatment period and for 28 days after discontinuation of the study drug.
  • Women of childbearing potential must comply with scheduled pregnancy tests.
  • Ability to understand and sign the Informed Consent Form (ICF).

Exclusion criteria

  • Diagnosis of Acute Promyelocytic Leukemia (APL) or FAB subtype M3 AML.
  • Patients with a history of extramedullary leukemia, unless central nervous system (CNS) involvement is controlled.
  • Laboratory values that do not meet the following criteria: Total Bilirubin ≤ 1.5 × Upper Limit of Normal (ULN); Serum Creatinine ≤ 2.5 × ULN; Absolute Neutrophil Count (ANC) > 0.5 × 10⁹/L; Platelet Count ≥ 30 × 10⁹/L.
  • Uncontrolled comorbidities, including but not limited to ongoing or active uncontrolled infection, symptomatic congestive heart failure, unstable angina, arrhythmia, or psychiatric illness/social situations that would compromise compliance with the protocol.
  • History of AML that was refractory to or did not achieve remission with prior treatment containing Venetoclax, Chidamide, or Azacitidine.
  • History of hypersensitivity to any component of the study protocol.
  • Pregnant women.
  • Patients with active Central Nervous System (CNS) disease.
  • Patients with Relapsed or Refractory (R/R) AML.
  • Patients who have undergone Hematopoietic Stem Cell Transplantation (HSCT).

Treatment and study plan

Cohort 1 (MRD-Negative Patients): 61 subjects

Drug

Chidamide (C): 5 mg, orally, once daily, Days 1-14. Azacitidine (A): 50 mg/m², subcutaneous injection, Days 1-5. Venetoclax (B): 400 mg, orally, once daily (QD), Days 1-14. Cycle: 28 days per cycle, for a total of 12 cycles.

Other names: MRD-Negative Patients

Cohort 2 (MRD-Persistent Positive Patients): 43 subjects

Drug

Chidamide (C): 5 mg, orally, once daily, Days 1-28. Azacitidine (A): 50 mg/m², subcutaneous injection, Days 1-5. Venetoclax (B): 400 mg, orally, once daily (QD), Days 1-14. Cycle: 28 days per cycle, for a total of 12 cycles.

Other names: MRD-Persistent Positive Patients

Primary outcomes

  1. Relapse-Free Survival (RFS)

    Time frame: 1-year RFS rate

    Relapse-Free Survival (RFS) is defined as the time interval from the date of enrollment (or achievement of Complete Remission) to the date of hematologic relapse, the occurrence of a second primary malignancy, or death from any cause, whichever occurs first.

    ● Endpoint Event: An "event" for RFS analysis is recorded when:

    • Hematologic Relapse: The patient shows definitive evidence of AML recurrence (e.g., blast count > 5% in bone marrow, or reappearance of blasts in peripheral blood).
    • Death: The patient dies due to any cause while in remission.

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: 2-year

    Overall Survival (OS) is defined as the time interval from the date of enrollment (or randomization) to the date of death from any cause.

    Endpoint Event: The primary event for the analysis is death from any cause (whether related to the disease, treatment, or other causes).

    Censoring: Patients who are still alive at the time of the final data cutoff, or who are lost to follow-up, will be censored at the date of their last known contact (last known alive date).

  2. Event-Free Survival (EFS)

    Time frame: 2-year

    Event-Free Survival (EFS) is defined as the time interval from the date of enrollment (or start of treatment) to the date of the first occurrence of any of the following events:

    Relapse: Hematologic recurrence of Acute Myeloid Leukemia (e.g., reappearance of blasts in bone marrow or peripheral blood).

    Death: Death from any cause (whether related to the disease, treatment, or other causes).

    Treatment Failure: (Optional, depending on protocol strictness) Failure to achieve response, or discontinuation of treatment due to toxicity or progressive disease before relapse.

    Censoring:

    Patients who do not experience any of the above events by the time of the final data cutoff, or who are lost to follow-up, will be censored at the date of their last adequate assessment.

  3. Duration of Remission (CRd)

    Time frame: 2-year

    Duration of Remission (CRd) is defined as the time interval from the date of first documented Complete Remission (CR) (or the date of enrollment if the patient is already in CR at baseline) to the date of relapse or death from any cause, whichever occurs first.

    Endpoint Event: An "event" for CRd analysis is recorded when:

    Relapse: The patient shows definitive evidence of AML recurrence (e.g., blast count > 5% in bone marrow, or reappearance of blasts in peripheral blood).

    Death: The patient dies while in remission. Censoring: Patients who are still alive and have not relapsed at the time of the final data cutoff are censored at the date of their last adequate assessment.

  4. Safety Evaluation

    Time frame: 2-year

    All Adverse Events (AEs) occurring during the clinical study, including abnormal clinical symptoms, vital signs, and laboratory findings, will be described in detail.

    Clinical characteristics, severity, onset time, duration, management, and outcomes of these events will be recorded.

    The relationship between these events and the study drugs will be assessed. Hematologic and non-hematologic toxicities will be graded according to the NCI-CTCAE v5.0 criteria.

  5. Analysis of MRD Dynamics and Prognostic Impact

    Time frame: 2-year

    Evaluation of the kinetic impact of Chidamide combined with Venetoclax and Azacitidine maintenance therapy on Measurable Residual Disease (MRD) and its correlation with prognosis.

Study contacts

Contact information is provided by the study sponsor or research team.

Weiming Li, Ph.D.

CONTACT

[email protected]

027-85726375

Sponsors and collaborators

Lead sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Other

Registry information

Official study title

Efficacy and Safety of Maintenance Treatment With Chidamide, Venetoclax, and Azacitidine for Treatment-Naive Acute Myeloid Leukemia Patients Achieving Complete Remission: A Multicenter Study

Acronym: ABC-Maint

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Apr 9, 2026
Registry last updated
Apr 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.